Nanobiotix

Yahoo Finance • 10 days ago

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Market: Eur... Full story

Yahoo Finance • 10 days ago

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 14 nov. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext Compartiment... Full story

Yahoo Finance • 11 days ago

NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations

Four new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial proprietary internal pipeline of Nanoprimer products in addition to external collaborationsNew in... Full story

Yahoo Finance • 11 days ago

NANOBIOTIX annonce les avancées de sa plateforme de nanoprimer Curadigm avec une mise à jour des plans de développement pour son pipeline interne et des collaborations externes

Quatre nouvelles demandes de brevets déposées visant à étendre la propriété intellectuelle de la plateforme de nanoprimer Curadigm et contribuer au premier pipeline interne et propriétaire de produits associés avec un nanoprimer, en plus d... Full story

Yahoo Finance • 24 days ago

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancerFinancing establishes financial foundation toward self-su... Full story

Yahoo Finance • 24 days ago

NANOBIOTIX annonce un accord stratégique avec HealthCare Royalty pour un montant maximum de 71 millions de dollars et prolonge ainsi son horizon de trésorerie pour une croissance durable

Les 71 millions de dollars américains permettraient à Nanobiotix d’étendre son horizon de trésorerie jusqu’au début de l’année 2028.Cette opération donne à Nanobiotix la capacité financière de se développer au-delà des jalons opérationnels... Full story

Yahoo Finance • last month

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control

PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilitie... Full story

Yahoo Finance • last month

NANOBIOTIX annonce des mises à jour sur le programme clinique de JNJ-1900 (NBTXR3) à la suite du transfert de sponsorship et du contrôle opérationnel de l’essai de Phase 3 en cours dans le cancer de la tête et du cou

PARIS et CAMBRIDGE, Mass., 24 oct. 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur... Full story

Yahoo Finance • 2 months ago

Nanobiotix gains after early-stage trial data for J&J-partnered cancer drug

[Cancer cells vis] koto_feja Nanobiotix (NASDAQ:NBTX [https://seekingalpha.com/symbol/NBIX]) traded higher on Thursday after the French biotech announced initial results from a Phase 1 trial for JNJ-1900 (NBTXR3), a cancer injection devel... Full story

Yahoo Finance • 2 months ago

Nanobiotix Says Early Trial Results Support JNJ-1900 With Chemoradiation in Esophageal Cancer

Nanobiotix (NBTX) reported early results from the first two cohorts of a phase 1 trial testing its r PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer

Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective response rate (ORR); 6 complete responses a... Full story

Yahoo Finance • 2 months ago

NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage

Le traitement a été bien toléré et la faisabilité de l’injection a été confirmée chez les 13 patients atteints d’adénocarcinome de l’œsophage localement avancé.Le taux de contrôle de la maladie (DCR, disease control rate) était de 85 % (11... Full story

Yahoo Finance • 2 months ago

Nanobiotix S.A. GAAP EPS of -€0.11, revenue of €26.6M

* Nanobiotix S.A. press release [https://seekingalpha.com/pr/20249945-nanobiotix-provides-business-update-and-reports-half-year-2025-financial-results] (OTC:NNBXF [https://seekingalpha.com/symbol/NNBXF]): 1H GAAP EPS of -€0.11. * Reven... Full story

Yahoo Finance • 2 months ago

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results

PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilitie... Full story

Yahoo Finance • 2 months ago

NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2025

PARIS et CAMBRIDGE, Mass., 30 sept. 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées su... Full story

Yahoo Finance • 2 months ago

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41) disease control rate (“DCR”) and 37% (15/41) objective response rate (“OR... Full story

Yahoo Finance • 2 months ago

NANOBIOTIX annonce de nouveaux résultats de Phase 1 qui continuent de confirmer le potentiel de JNJ-1900 (NBTXR3), avec un anti-PD-1, en tant que potentielle nouvelle option thérapeutique de première ou deuxième ligne ou plus dans le CETEC R/M naïf ou résistant aux anti-PD-1

Le traitement continue de présenter un profil de tolérance favorable avec une faisabilité d’injection confirmée chez les 103 patients lourdement prétraités atteints de CETEC R/M naïfs ou résistants aux anti-PD-1.Chez les patients naïfs aux... Full story

Yahoo Finance • 2 months ago

Biggest stock movers Thursday: INTC, NVO, ETNB, REPL, and more

[Stock market trading, financial data graph chart, data visualization, Business arrow graph chart] Rasi Bhadramani Stock futures exhibited mixed performance on Thursday as investors digested the Federal Reserve’s first rate cut since Dece... Full story

Yahoo Finance • 2 months ago

Nanobiotix soars on positive phase 1 results for JNJ-1900 in melanoma

[Pharmaceutical industry and drug manufacturing] Extreme Media Nanobiotix (NASDAQ:NBTX [https://seekingalpha.com/symbol/NBTX]) shares rose sharply in Thursday's premarket trading after the company announced new Phase 1 study results for J... Full story

Yahoo Finance • 2 months ago

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D) established at 33% of gros... Full story